Cellon debuts sterile single-use containers

Published: 27-Apr-2012
Pharmaceutical

The range is ideal for use in the handling and storage of biologicals

A new range of sterile single-use containers for storage, freezing, and manipulation of biological solutions has been launched by Luxembourg-based Cellon SA, a provider of products and services for vaccine production and bioprocessing.

Called PharmaTainer, the line of products are a range of low particulate, single use bottles and carboys for the storage/transport of bulk vaccines, biopharmaceuticals, culture media and other biotech materials.

The plastic containers are injection blow moulded in an ISO Class 5 (Class100) environment and radiation sterilised. These rigid ultra-clean containers are available in sizes from 125ml to 20L. They are manufactured from resins approved for medical applications in PET or polycarbonate with HDPE closures.

PharmaTainer packaging features three inner layers of poly wrapping to facilitate delivery into cleanroom areas. The inner most layer is vacuum-sealed providing tamper evidence and assurance of an intact sterility barrier.

The range of products feature traceability down to the individual container. Each bottle/carboy is printed with a unique serial number, batch number, expiration date and a machine-readable data matrix. The machine-readable serial number can be readily integrated with the user’s inventory management system.

All PharmaTainer products are produced in a new, moulding facility, dedicated solely to production of sterile, single-use products for biotechnology industries.

European customers may get further information at www.cellon.lu or by email sales@cellon.lu. The products are distributed by Biofluid Focus in North American (www.biofluidfocus.com).




See more

You may also like

Manufacturing

3i builds single-use bioprocessing platform using three acquisitions

Read more
The UK-based company has acquired Cellon, Silicone Altimex and TBL Performance Plastics to establish a platform serving the high growth single-use technology market

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258 The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
  3. Lyocontract invests €50m in new freeze-drying facility with Syntegon vial line German CDMO Lyocontract has begun construction of a €50m expansion in Ilsenburg, partnering with Syntegon to install a complete vial filling and lyophilisation line for sterile freeze-dried pharmaceuticals
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Semaglutide patent cliff: pharma industry braces for impact With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
  5. Coriolis Pharma opens US headquarters and laboratory at Research Triangle Park in North Carolina Biopharmaceutical services specialist Coriolis Pharma has launched its first US base at the Alexandria Centre for Advanced Technologies, offering North American clients direct access to formulation development, particle analysis and drug product characterisation services

Upcoming event

Cleanroom Technology Awards 2026

13 April | Virtual See all

You may also like

Manufacturing

3i builds single-use bioprocessing platform using three acquisitions

The UK-based company has acquired Cellon, Silicone Altimex and TBL Performance Plastics to establish a platform serving the high growth single-use technology market
Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

The challenges of developing combination products

Regulatory complexity and the case for a holistic development strategy
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Subscribe now